Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation

Bone Marrow Transplantation volume 38, pages 211–216 (2006)Cite this article

Abstract

We conducted a retrospective analysis of 50 lymphoma patients (Hodgkin's disease and non-Hodgkin's lymphoma) who had an 18F-fluoro-deoxyglucose positron emission tomography (FDG-PET) scan after at least two cycles of salvage chemotherapy and before autologous stem cell transplantation (ASCT) at our institution. The patients were categorized into FDG-PET negative (N=32) and positive (N=18) groups. The median follow-up after ASCT was 19 months (range: 3–59). In the FDG-PET-negative group, the median progression-free survival (PFS) was 19 months (range: 2–59) with 15 (54%) patients without progression at 12 months after ASCT. The median overall survival (OS) for this group was not reached. In the FDG-PET-positive group, the median PFS was 5 months (range: 1–19) with only one (7%) patient without progression at 12 months after ASCT. The median OS was 19 months (range: 1–34). In the FDG-PET-negative group, chemotherapy-resistant patients by CT-based criteria had a comparable outcome to those with chemotherapy-sensitive disease. A positive FDG-PET scan after salvage chemotherapy and prior ASCT indicates an extremely poor chance of durable response after ASCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006.

    Article  CAS  PubMed  Google Scholar 

  2. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C . Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252–259.

    Article  CAS  PubMed  Google Scholar 

  3. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493–1498.

    Article  CAS  PubMed  Google Scholar 

  4. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  5. Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20: 467–475.

    CAS  PubMed  Google Scholar 

  6. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J . Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124: 645–652.

    Article  PubMed  Google Scholar 

  7. Bartlett NL . Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy. Hematology (Am Soc Hematol Educ Program) 2005, 245–251.

    Article  Google Scholar 

  8. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.

    Article  CAS  PubMed  Google Scholar 

  9. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630–1636.

    Article  CAS  PubMed  Google Scholar 

  10. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071.

    Article  CAS  PubMed  Google Scholar 

  11. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429–433.

    CAS  PubMed  Google Scholar 

  12. Elstrom R, Guan LF, Baker G, Nakhoda K, Vergilio JA, Zhuang H et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875–3876.

    Article  CAS  PubMed  Google Scholar 

  13. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52–59.

    Article  CAS  PubMed  Google Scholar 

  14. Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652–4661.

    Article  PubMed  Google Scholar 

  15. Ho CL, Dehdashti F, Griffeth LK, Buse PE, Balfe DM, Siegel BA . FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr 1996; 20: 363–369.

    Article  CAS  PubMed  Google Scholar 

  16. Al-Sugair A, Coleman RE . Applications of PET in lung cancer. Semin Nucl Med 1998; 28: 303–319.

    Article  CAS  PubMed  Google Scholar 

  17. Duarte PS, Zhuang H, Castellucci P, Alavi A . The receiver operating characteristic curve for the standard uptake value in a group of patients with bone marrow metastasis. Mol Imaging Biol 2002; 4: 157–160.

    Article  PubMed  Google Scholar 

  18. Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME et al. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 2003; 124: 608–613.

    Article  PubMed  Google Scholar 

  19. Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16: 260–267.

    Article  CAS  PubMed  Google Scholar 

  20. Schot B, van Imhoff G, Pruim J, Sluiter W, Vaalburg W, Vellenga E . Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol 2003; 123: 282–287.

    Article  PubMed  Google Scholar 

  21. Cremerius U, Fabry U, Wildberger JE, Zimny M, Reinartz P, Nowak B et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 30: 103–111.

    Article  CAS  PubMed  Google Scholar 

  22. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102: 53–59.

    Article  CAS  PubMed  Google Scholar 

  23. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461–467.

    Article  CAS  PubMed  Google Scholar 

  24. Freudenberg LS, Antoch G, Schutt P, Beyer T, Jentzen W, Muller SP et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 325–329.

    Article  CAS  PubMed  Google Scholar 

  25. Schoder H, Larson SM, Yeung HW . PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004; 45 (Suppl 1): 72S–81S.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA, USA

    J Svoboda, C Andreadis, E A Chong, L H Downs, S M Luger, D L Porter, S Nasta, D Tsai, A W Loren, D L Siegel, E Glatstein, E A Stadtmauer & S J Schuster

  2. Hematology and Oncology Division, University of Michigan, Ann Arbor, MI, USA

    R Elstrom

  3. Nuclear Medicine Division, University of Pennsylvania, Philadelphia, PA, USA

    A Berkowitz & A Alavi

Authors
  1. J Svoboda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Andreadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Elstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E A Chong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L H Downs
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Berkowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S M Luger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D L Porter
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Nasta
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A W Loren
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D L Siegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E Glatstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A Alavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. E A Stadtmauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S J Schuster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Svoboda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Svoboda, J., Andreadis, C., Elstrom, R. et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 38, 211–216 (2006). https://doi.org/10.1038/sj.bmt.1705416

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705416

Keywords

This article is cited by

Search

Advanced search

Quick links